Results 91 to 100 of about 30,272 (291)

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors

iScience, 2021
Summary: Despite the remarkable success of chimeric antigen receptor (CAR)-T cells against hematologic malignancies, severe off-tumor effects have constrained their use against solid tumors. Recently, CAR-engineered natural killer (NK) cells have emerged
Ana L. Portillo, Richard Hogg, Sophie M. Poznanski, Eduardo A. Rojas, Niamh J. Cashell, Joanne A. Hammill, Marianne V. Chew, Mira M. Shenouda, Tyrah M. Ritchie, Quynh T. Cao, Jeremy A. Hirota, Sukhbinder Dhesy-Thind, Jonathan L. Bramson, Ali A. Ashkar   +13 more
doaj   +1 more source

Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing [PDF]

, 2023
Background: With increasing clinical use of NK-92 cells and their CAR-modified derivatives in cancer immunotherapy, there is a growing demand for efficient production processes of these “off-the-shelf” therapeutics.
Beckmann, Jana, Blumert, Conny, Braun, Armin, Böhlen, Sebastian, Dehmel, Susann, Dünkel, Anna, Fricke, Stephan, Kistenmacher, Ann-Kathrin, Klöß, Stephan, Kossatz-Böhlert, Uta, Kämpf, Christoph, Köhl, Ulrike, König, Ulla, Löffler, Dennis, Makert, Gustavo R., Morgan, Michael, Reiche, Kristin, Schambach, Axel, Sommer, Charline, Standfest, Bastian, Thoma, Martin, Tretbar, Uta Sandy, Ulbert, Sebastian, Walcher, Lia, Ziemann, Christina   +24 more
core   +1 more source

CD33KO-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia

Journal for ImmunoTherapy of Cancer
Background Patients with acute myeloid leukemia (AML) are often older, which brings challenges of endurance and persistent efficacy of autologous chimeric antigen receptor (CAR)-T cell therapies. Allogenic CAR-natural killer (NK) cell therapies may offer
Qi Chen, Qi Zhang, Xin Du, Xiaofan Zhu, Yao Wang, Yi Chen, Fan Zhang, Fangxiao Hu, Dehao Huang, Qitong Weng, Jinyong Wang, Lijuan Liu, Aibin Liang, Jiaxin Wu, Yanhong Liu, Pengcheng Liu, Wenbin Qian, Xiujuan Zheng, Zhiqian Wang, Ziyun Xiao, Yunqing Lin, Leqiang Zhang, Chengxiang Xia, Yanping Zhu, Hanmeng Qi, Yiyuan Shen, Chenyuan Zhang, Jiacheng Xu, Yaoqin Zhao, Tongjie Wang, Mengyun Zhang, Minming Li, Wenyu Yang, Tianyuan Hu   +33 more
doaj   +1 more source

PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe

Advanced Science, EarlyView.
This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao, Wenzhu Hu, Du Tang, Xinxin Liu, Kun Yu, Lixia Feng, Minyu Liao, Wang Lin, Wenqiang Zhu, Sanjay Rajagopalan, Xiaoli Lan, Jixin Zhong, Dao Wen Wang, Dawei Jiang, Xiaoquan Rao   +14 more
wiley   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential

Experimental Hematology & Oncology, 2022
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent achievement in the clinical immunotherapy of hematological malignant tumors, leading to a rapid development of cellular immunotherapy in cancer treatment.
Xiao Wang, Xuejiao Yang, Xiang Yuan, Wenbo Wang, Yueying Wang   +4 more
doaj   +1 more source

Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells [PDF]

, 2020
ABSTRACTSARS-CoV-2, which causes COVID-19 disease, is one of greatest global pandemics in history. No effective treatment is currently available for severe COVID-19 disease. One strategy for implementing cell-based immunity involves the use of chimeric antigen receptor (CAR) technology.
Minh Ma, Saiaditya Badeti, Ke Geng, Dongfang Liu   +3 more
openaire   +2 more sources

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Perspective: IL-15 cytokine-armored NK cells as ready-to-use immunotherapy for diverse malignancies: therapeutic potential and toxicity risks [PDF]

Natural killer (NK) cells have been engineered to express chimeric antigen receptors (CARs) to enhance their cytotoxic capabilities through CAR-mediated activation, a strategy that has yielded promising advancements in cancer treatment in recent pre ...
Beau Webber, Beau Webber, Beau Webber, Branden S. Moriarity, Branden S. Moriarity, Branden S. Moriarity, Joshua Kreuger, Joshua Kreuger, Joshua Kreuger, Matt Johnson, Matt Johnson, Matt Johnson, Scott L. Baughan, Scott L. Baughan, Timothy Folsom, Timothy Folsom, Timothy Folsom   +16 more
core   +1 more source